We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Epilepsy - Pipeline Review, H1 2019

Published: April 2019
Pages: 512
Code: 3A6A97C2AB5F9758E5AA5A861644E161
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 2,000.00
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide , provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide , provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 1, 8, 23, 23, 1, 82, 16 and 4 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 1, 21 and 3 molecules, respectively.
Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
  • - The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • - The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • - The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • - The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

Companies Mentioned

Aadi Bioscience Inc
Adamas Pharmaceuticals Inc
Advicenne SA
Aequus Pharmaceuticals Inc
Aevi Genomic Medicine Inc
Affectis Pharmaceuticals AG
AMO Pharma Ltd
Anavex Life Sciences Corp
Aphios Corp
Aquestive Therapeutics Inc
Asklepios BioPharmaceutical Inc
Aucta Pharmaceuticals LLC
BCWorld Pharm Co Ltd
Bial - Portela & Ca SA
Biogen Inc
BioHealthonomics Inc
Biovista Inc
Bloom Science Inc
Catalyst Pharmaceuticals Inc
Cavion LLC
Celgene Corp
Cellix Bio Pvt Ltd
Cerecor Inc
Cerevel Therapeutics LLC
CombiGene AB
Crossject SA
Eisai Co Ltd
Engage Therapeutics Inc
Eton Pharmaceuticals Inc
Genus Lifesciences Inc
Gilead Sciences Inc
Glialogix Inc
GW Pharmaceuticals Plc
Idorsia Pharmaceutical Ltd
Insys Therapeutics Inc
Ionis Pharmaceuticals Inc
Iproteos SL
Johnson & Johnson
Karessa Pharma Holding AB
Knopp Biosciences LLC
Lead Discovery Center GmbH
Marinus Pharmaceuticals Inc
Medicure Inc
NeuCyte Inc
Neurelis Inc
Neurocrine Biosciences Inc
NeuroCycle Therapeutics GmbH
Neuron Biopharma SA
New Amsterdam Sciences Inc
NoNO Inc
Novartis AG
OPKO Health Inc
Ovid Therapeutics Inc
Pairnomix LLC
Panorama Research Inc
Pfizer Inc
Promius Pharma LLC
PTC Therapeutics Inc
Recursion Pharmaceuticals Inc
reMYND NV
Sage Therapeutics Inc
Saniona AB
Serina Therapeutics Inc
Simcere Pharmaceutical Group
SK Biopharmaceuticals Co Ltd
Stoke Therapeutics Inc
Suda Pharmaceuticals Ltd
Sumitomo Dainippon Pharma Co Ltd
Supernus Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
The Cell-Factory BVBA
UCB SA
Ultragenyx Pharmaceutical Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
Xenon Pharmaceuticals Inc
XERIS Pharmaceuticals Inc
Xi'an Libang Pharmaceuticals Co Ltd
Zhejiang Conba Pharmaceutical Co Ltd
Zogenix Inc
Zynerba Pharmaceuticals Inc

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics. Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Add to basket
  • Table of Contents
  • Introduction
  • Epilepsy - Overview
  • Epilepsy - Therapeutics Development
  • Epilepsy - Therapeutics Assessment
  • Epilepsy - Companies Involved in Therapeutics Development
  • Epilepsy - Drug Profiles
  • Epilepsy - Dormant Projects
  • Epilepsy - Discontinued Products
  • Epilepsy - Product Development Milestones
  • Appendix
  • List of Tables
  • Number of Products under Development for Epilepsy, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Universities/Institutes, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Epilepsy - Pipeline by Aadi Bioscience Inc, H1 2019
  • Epilepsy - Pipeline by Adamas Pharmaceuticals Inc, H1 2019
  • Epilepsy - Pipeline by Advicenne SA, H1 2019
  • Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, H1 2019
  • Epilepsy - Pipeline by Aevi Genomic Medicine Inc, H1 2019
  • Epilepsy - Pipeline by Affectis Pharmaceuticals AG, H1 2019
  • Epilepsy - Pipeline by AMO Pharma Ltd, H1 2019
  • Epilepsy - Pipeline by Anavex Life Sciences Corp, H1 2019
  • Epilepsy - Pipeline by Aphios Corp, H1 2019
  • Epilepsy - Pipeline by Aquestive Therapeutics Inc, H1 2019
  • Epilepsy - Pipeline by Asklepios BioPharmaceutical Inc, H1 2019
  • Epilepsy - Pipeline by Aucta Pharmaceuticals LLC, H1 2019
  • Epilepsy - Pipeline by BCWorld Pharm Co Ltd, H1 2019
  • Epilepsy - Pipeline by Bial - Portela & Ca SA, H1 2019
  • Epilepsy - Pipeline by Biogen Inc, H1 2019
  • Epilepsy - Pipeline by BioHealthonomics Inc, H1 2019
  • Epilepsy - Pipeline by Biovista Inc, H1 2019
  • Epilepsy - Pipeline by Bloom Science Inc, H1 2019
  • Epilepsy - Pipeline by Catalyst Pharmaceuticals Inc, H1 2019
  • Epilepsy - Pipeline by Cavion LLC, H1 2019
  • Epilepsy - Pipeline by Celgene Corp, H1 2019
  • Epilepsy - Pipeline by Cellix Bio Pvt Ltd, H1 2019
  • Epilepsy - Pipeline by Cerecor Inc, H1 2019
  • Epilepsy - Pipeline by Cerevel Therapeutics LLC, H1 2019
  • Epilepsy - Pipeline by CombiGene AB, H1 2019
  • Epilepsy - Pipeline by Crossject SA, H1 2019
  • Epilepsy - Pipeline by Eisai Co Ltd, H1 2019
  • Epilepsy - Pipeline by Engage Therapeutics Inc, H1 2019
  • Epilepsy - Pipeline by Eton Pharmaceuticals Inc, H1 2019
  • Epilepsy - Pipeline by Genus Lifesciences Inc, H1 2019
  • Epilepsy - Pipeline by Gilead Sciences Inc, H1 2019
  • Epilepsy - Pipeline by Glialogix Inc, H1 2019
  • Epilepsy - Pipeline by GW Pharmaceuticals Plc, H1 2019
  • Epilepsy - Pipeline by Idorsia Pharmaceutical Ltd, H1 2019
  • Epilepsy - Pipeline by Insys Therapeutics Inc, H1 2019
  • Epilepsy - Pipeline by Ionis Pharmaceuticals Inc, H1 2019
  • Epilepsy - Pipeline by Iproteos SL, H1 2019
  • Epilepsy - Pipeline by Johnson & Johnson, H1 2019
  • Epilepsy - Pipeline by Karessa Pharma Holding AB, H1 2019
  • Epilepsy - Pipeline by Knopp Biosciences LLC, H1 2019
  • Epilepsy - Pipeline by Lead Discovery Center GmbH, H1 2019
  • Epilepsy - Pipeline by Marinus Pharmaceuticals Inc, H1 2019
  • Epilepsy - Pipeline by Medicure Inc, H1 2019
  • Epilepsy - Pipeline by NeuCyte Inc, H1 2019
  • Epilepsy - Pipeline by Neurelis Inc, H1 2019
  • Epilepsy - Pipeline by Neurocrine Biosciences Inc, H1 2019
  • Epilepsy - Pipeline by NeuroCycle Therapeutics GmbH, H1 2019
  • Epilepsy - Pipeline by Neuron Biopharma SA, H1 2019
  • Epilepsy - Pipeline by New Amsterdam Sciences Inc, H1 2019
  • Epilepsy - Pipeline by NoNO Inc, H1 2019
  • Epilepsy - Pipeline by Novartis AG, H1 2019
  • Epilepsy - Pipeline by OPKO Health Inc, H1 2019
  • Epilepsy - Pipeline by Ovid Therapeutics Inc, H1 2019
  • List of Figures
  • Number of Products under Development for Epilepsy, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Top 10 Routes of Administration, H1 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Keywords
;